title: Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
authors: Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
authors: Bernhard
authors: B
authors: Reis
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Lori
authors: L
authors: Jukofsky
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Gong
authors: G
authors: Chen
authors: Seragnoli Institute of Hematology, Bologna University School of Medicine, Italy.
authors: Giovanni
authors: G
authors: Martinelli
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Hua
authors: H
authors: Zhong
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: W Venus
authors: WV
authors: So
authors: Department of Haematology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia.
authors: Michael J
authors: MJ
authors: Dickinson
authors: Beatson West of Scotland Cancer Center, Gartnavel General Hospital, Glasgow, United Kingdom.
authors: Mark
authors: M
authors: Drummond
authors: Division of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada.
authors: Sarit
authors: S
authors: Assouline
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Maneja
authors: M
authors: Hashemyan
authors: Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland.
authors: Michel
authors: M
authors: Theron
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Steven
authors: S
authors: Blotner
authors: Department of Hematology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
authors: Je-Hwan
authors: JH
authors: Lee
authors: Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
authors: Margaret
authors: M
authors: Kasner
authors: Department of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea.
authors: Sung-Soo
authors: SS
authors: Yoon
authors: Roche Innovation Center Penzberg, Roche Pharma Research and Early Development, Germany.
authors: Ruediger
authors: R
authors: Rueger
authors: New York Medical College, Valhalla, NY, USA.
authors: Karen
authors: K
authors: Seiter
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Steven A
authors: SA
authors: Middleton
authors: University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
authors: Kevin R
authors: KR
authors: Kelly
authors: Hematology, Institut Paoli Calmettes, Marseilles, France.
authors: Norbert
authors: N
authors: Vey
authors: Princess Margaret Hospital, Toronto, ON, Canada.
authors: Karen
authors: K
authors: Yee
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Gwen
authors: G
authors: Nichols
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA.
authors: Lin-Chi
authors: LC
authors: Chen
authors: Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA william.pierceall@roche.com.
authors: William E
authors: WE
authors: Pierceall
mesh_terms: D001752:Blast Crisis / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy / Q000401:mortality; D008297:Male; D051736:Proto-Oncogene Proteins c-mdm2 / Q000096:biosynthesis*; D011759:Pyrrolidines / Q000008:administration & dosage* / Q000009:adverse effects; D062366:para-Aminobenzoates / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D011759:Pyrrolidines; C586849:RG7388; D062366:para-Aminobenzoates; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2
keywords: AML; MDM2 antagonism; complementary diagnostics; flow cytometry; idasanutlin